Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,032 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.
Fisher BA, Veenith T, Slade D, Gaskell C, Rowland M, Whitehouse T, Scriven J, Parekh D, Balasubramaniam MS, Cooke G, Morley N, Gabriel Z, Wise MP, Porter J, McShane H, Ho LP, Newsome PN, Rowe A, Sharpe R, Thickett DR, Bion J, Gates S, Richards D, Kearns P; CATALYST investigators. Fisher BA, et al. Among authors: porter j. Lancet Respir Med. 2022 Mar;10(3):255-266. doi: 10.1016/S2213-2600(21)00460-4. Epub 2021 Dec 16. Lancet Respir Med. 2022. PMID: 34922649 Free PMC article. Clinical Trial.
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study.
Drake TM, Docherty AB, Harrison EM, Quint JK, Adamali H, Agnew S, Babu S, Barber CM, Barratt S, Bendstrup E, Bianchi S, Villegas DC, Chaudhuri N, Chua F, Coker R, Chang W, Crawshaw A, Crowley LE, Dosanjh D, Fiddler CA, Forrest IA, George PM, Gibbons MA, Groom K, Haney S, Hart SP, Heiden E, Henry M, Ho LP, Hoyles RK, Hutchinson J, Hurley K, Jones M, Jones S, Kokosi M, Kreuter M, MacKay LS, Mahendran S, Margaritopoulos G, Molina-Molina M, Molyneaux PL, O'Brien A, O'Reilly K, Packham A, Parfrey H, Poletti V, Porter JC, Renzoni E, Rivera-Ortega P, Russell AM, Saini G, Spencer LG, Stella GM, Stone H, Sturney S, Thickett D, Thillai M, Wallis T, Ward K, Wells AU, West A, Wickremasinghe M, Woodhead F, Hearson G, Howard L, Baillie JK, Openshaw PJM, Semple MG, Stewart I, Jenkins RG; ISARIC4C Investigators. Drake TM, et al. Among authors: porter jc. Am J Respir Crit Care Med. 2020 Dec 15;202(12):1656-1665. doi: 10.1164/rccm.202007-2794OC. Am J Respir Crit Care Med. 2020. PMID: 33007173 Free PMC article.
Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
Dushianthan A, Clark H, Madsen J, Mogg R, Matthews L, Berry L, de la Serna JB, Batchelor J, Brealey D, Hussell T, Porter J, Djukanovic R, Feelisch M, Postle A, Grocott MPW. Dushianthan A, et al. Among authors: porter j. Trials. 2020 Dec 10;21(1):1014. doi: 10.1186/s13063-020-04944-5. Trials. 2020. PMID: 33302976 Free PMC article. Clinical Trial.
Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy.
Mehta P, Bunker CB, Ciurtin C, Porter JC, Chambers RC, Papdopoulou C, Garthwaite H, Hillman T, Heightman M, Howell KJ, Eleftheriou D, Denton CP. Mehta P, et al. Among authors: porter jc. Lancet Infect Dis. 2021 Jul;21(7):912. doi: 10.1016/S1473-3099(21)00133-X. Epub 2021 Mar 8. Lancet Infect Dis. 2021. PMID: 33705725 Free PMC article. No abstract available.
Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID).
Wild JM, Porter JC, Molyneaux PL, George PM, Stewart I, Allen RJ, Aul R, Baillie JK, Barratt SL, Beirne P, Bianchi SM, Blaikley JF, Brooke J, Chaudhuri N, Collier G, Denneny EK, Docherty A, Fabbri L, Gibbons MA, Gleeson FV, Gooptu B, Hall IP, Hanley NA, Heightman M, Hillman TE, Johnson SR, Jones MG, Khan F, Lawson R, Mehta P, Mitchell JA, Platé M, Poinasamy K, Quint JK, Rivera-Ortega P, Semple M, Simpson AJ, Smith D, Spears M, Spencer LG, Stanel SC, Thickett DR, Thompson AAR, Walsh SL, Weatherley ND, Weeks ME, Wootton DG, Brightling CE, Chambers RC, Ho LP, Jacob J, Piper Hanley K, Wain LV, Jenkins RG. Wild JM, et al. Among authors: porter jc. BMJ Open Respir Res. 2021 Sep;8(1):e001049. doi: 10.1136/bmjresp-2021-001049. BMJ Open Respir Res. 2021. PMID: 34556492 Free PMC article.
Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial.
Tornling G, Batta R, Porter JC, Williams B, Bengtsson T, Parmar K, Kashiva R, Hallberg A, Cohrt AK, Westergaard K, Dalsgaard CJ, Raud J. Tornling G, et al. Among authors: porter jc. EClinicalMedicine. 2021 Nov;41:101152. doi: 10.1016/j.eclinm.2021.101152. Epub 2021 Oct 24. EClinicalMedicine. 2021. PMID: 34723163 Free PMC article.
Large scale clinical trials: lessons from the COVID-19 pandemic.
Horsley AR, Pearmain L, Knight S, Schindler N, Wang R, Bennett M, Robey RC, Davies JC, Djukanović R, Heaney LG, Hussell T, Marciniak SJ, McGarvey LP, Porter J, Wilkinson T, Brightling C, Ho LP. Horsley AR, et al. Among authors: porter j. BMJ Open Respir Res. 2022 Jun;9(1):e001226. doi: 10.1136/bmjresp-2022-001226. BMJ Open Respir Res. 2022. PMID: 35701071 Free PMC article.
Early-phase clinical trials in a pandemic: learning from the response to COVID-19.
Horsley A, Brightling C, Davies J, Djukanovic R, Heaney LG, Hussell T, Marciniak SJ, McGarvey L, Porter JC, Wilkinson T, Ho LP; NIHR Respiratory Translational Research Collaboration network. Horsley A, et al. Among authors: porter jc. Lancet Respir Med. 2022 Jul;10(7):625-627. doi: 10.1016/S2213-2600(22)00062-5. Epub 2022 Jun 13. Lancet Respir Med. 2022. PMID: 35709826 Free PMC article. No abstract available.
4,032 results